{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:51:32Z","timestamp":1788871892532,"version":"build-2803163510"},"reference-count":80,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Eosinophilic esophagitis (EoE) is a multifaceted disease characterized by a wide heterogeneity of clinical manifestations, endoscopic and histopathologic patterns, and responsiveness to therapy. From the perspective of an effective approach to the patient, the different inflammatory mechanisms involved in the pathogenesis of EoE and biologics, in particular monoclonal antibodies (mAbs), targeting these pathways are needed. Currently, the most relevant is dupilumab, which interferes with both interleukin (IL)-4 and IL-13 pathways by binding IL-4 receptor \u03b1, and is the only mAb approved by the European Medicine Agency and US Food and Drug Administration for the treatment of EoE. Other mAbs investigated include mepolizumab, reslizumab, and benralizumab (interfering with IL-5 axis), cendakimab and dectrekumab (anti-IL-13s), tezepelumab (anti-TSLP), lirentelimab (anti-SIGLEG-8), and many others. Despite the undeniable economic impact of biologic therapies, in the near future, there will be room for further reflection about the opportunity to prescribe biologic agents, not only as a last-line therapy in selected cases such as patients with comorbidities involving common pathways. Although recent findings are very encouraging, the road to permanent success in the treatment of EoE is still long, and further studies are needed to determine the long-term effects of mAbs and to discover new potential targets.<\/jats:p>","DOI":"10.3390\/ijms25031702","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T07:49:47Z","timestamp":1706600987000},"page":"1702","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs"],"prefix":"10.3390","volume":"25","author":[{"given":"Erminia","family":"Ridolo","sequence":"first","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Barone","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Ottoni","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Peveri","sequence":"additional","affiliation":[{"name":"Departmental Unit of Allergology, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Montagni","sequence":"additional","affiliation":[{"name":"Departmental Unit of Allergology, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Nicoletta","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.mcna.2018.08.009","article-title":"Eosinophilic Esophagitis","volume":"103","author":"Reed","year":"2019","journal-title":"Med. Clin. N. Am."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/apt.15231","article-title":"Systematic review with meta-analysis: The growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies","volume":"49","author":"Navarro","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jama.2021.14920","article-title":"Eosinophilic Esophagitis: A Review","volume":"326","author":"Muir","year":"2021","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.gastro.2022.03.025","article-title":"A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions","volume":"163","author":"Dellon","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.cgh.2017.06.036","article-title":"Health-Related Quality of Life and Costs Associated with Eosinophilic Esophagitis: A Systematic Review","volume":"4","author":"Mukkada","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/ajg.2013.71","article-title":"ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE)","volume":"108","author":"Dellon","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"ref_7","unstructured":"(2023, November 18). Jorveza|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jorveza."},{"key":"ref_8","unstructured":"(2023, November 18). FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder, Available online: www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-eosinophilic-esophagitis-chronic-immune-disorder."},{"key":"ref_9","unstructured":"(2023, November 18). Dupixent|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/dupixent."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.21037\/tgh-22-15","article-title":"EoE behaves as a unique Th2 disease: A narrative review","volume":"8","author":"Rabinowitz","year":"2023","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Massironi, S., Mulinacci, G., Gallo, C., Elvevi, A., Danese, S., Invernizzi, P., and Vespa, E. (2023). Mechanistic Insights into Eosinophilic Esophagitis: Therapies Targeting Pathophysiological Mechanisms. Cells, 12.","DOI":"10.3390\/cells12202473"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/cea.14196","article-title":"Eosinophilic esophagitis: Immune mechanisms and therapeutic targets","volume":"52","author":"Khokhar","year":"2022","journal-title":"Clin. Exp. Allergy"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.jaci.2018.03.017","article-title":"Solute carrier family 9, subfamily A, member 3 (SLC9A3)\/sodium-hydrogen exchanger member 3 (NHE3) dysregulation and dilated intercellular spaces in patients with eosinophilic esophagitis","volume":"142","author":"Zeng","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1053\/j.gastro.2020.07.035","article-title":"Increased Production of LIGHT by T Cells in Eosinophilic Esophagitis Promotes Differentiation of Esophageal Fibroblasts Toward an Inflammatory Phenotype","volume":"159","author":"Manresa","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.jaci.2014.04.004","article-title":"TGF-beta1-induced phospholamban expression alters esophageal smooth muscle cell contraction in patients with eosinophilic esophagitis","volume":"134","author":"Beppu","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.jaci.2010.08.050","article-title":"Mast cells infiltrate the esophageal smooth muscle in patients with eosinophilic esophagitis, express TGF-\u03b21, and increase esophageal smooth muscle contraction","volume":"126","author":"Aceves","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41385-022-00486-y","article-title":"The LIGHT switch: Mechanisms of fibroblast pathology in eosinophilic esophagitis","volume":"15","author":"Chua","year":"2022","journal-title":"Mucosal Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaci.2018.10.067","article-title":"Fibrostenotic eosinophilic esophagitis might reflect epithelial lysyl oxidase induction by fibroblast-derived TNF-\u03b1","volume":"144","author":"Kasagi","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S2468-1253(18)30096-7","article-title":"Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: A cross-sectional study","volume":"3","author":"Shoda","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of Dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.1073\/pnas.0802465105","article-title":"Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha1 and the type II IL-4 receptor in asthma pathogenesis","volume":"105","author":"Munitz","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1053\/j.gastro.2017.06.065","article-title":"Pathophysiology of Eosinophilic Esophagitis","volume":"154","author":"Aceves","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"603295","DOI":"10.3389\/fimmu.2020.603295","article-title":"Eosinophils in Eosinophilic Esophagitis: The Road to Fibrostenosis is Paved With Good Intentions","volume":"11","author":"Doyle","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2222.2009.03419.x","article-title":"Interleukin-13 directly promotes oesophagus production of CCL11 and CCL24 and the migration of eosinophils","volume":"40","author":"Neilsen","year":"2010","journal-title":"Clin. Exp. Allergy"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.jaci.2007.10.024","article-title":"IL-13 involvement in eosinophilic esophagitis: Transcriptome analysis and reversibility with glucocorticoids","volume":"120","author":"Blanchard","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s11894-023-00904-6","article-title":"Barrier Dysfunction in Eosinophilic Esophagitis","volume":"25","author":"McGowan","year":"2023","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e96789","DOI":"10.1172\/jci.insight.96789","article-title":"Synaptopodin is upregulated by IL-13 in eosinophilic esophagitis and regulates esophageal epithelial cell motility and barrier integrity","volume":"2","author":"Rochman","year":"2017","journal-title":"JCI Insight"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"G341","DOI":"10.1152\/ajpgi.00404.2017","article-title":"Filaggrin and tight junction proteins are crucial for IL-13-mediated esophageal barrier dysfunction","volume":"315","author":"Wu","year":"2018","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00535-018-1498-3","article-title":"Epithelial-stromal crosstalk and fibrosis in eosinophilic esophagitis","volume":"54","author":"Muir","year":"2019","journal-title":"J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"660","DOI":"10.4049\/jimmunol.1000471","article-title":"IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13R alpha 2-inhibited pathway","volume":"185","author":"Zuo","year":"2010","journal-title":"J. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults with Active Eosinophilic Esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S1542","DOI":"10.1016\/j.cgh.2022.07.020","article-title":"Real-World Efficacy of Dupilumab in Severe, Treatment-Refractory, and Fibrostenotic Patients with Eosinophilic Esophagitis","volume":"3","author":"Lee","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.anai.2022.12.014","article-title":"Clinical guidance for the use of dupilumab in eosinophilic esophagitis: A yardstick","volume":"130","author":"Aceves","year":"2023","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_37","unstructured":"(2023, November 18). Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients with Active Eosinophilic Esophagitis (EoE) (EoE KIDS), Available online: https:\/\/www.clinicaltrials.gov\/search?cond=NCT04394351."},{"key":"ref_38","unstructured":"(2023, November 18). A Study Assessing Esophageal Function and Remodeling with Dupilumab Compared with Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants with EoE (REMOdeling with Dupilumab in Eosinophilic Esophagitis Long-Term Trial), Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT06101095?cond=NCT06101095&rank=1."},{"key":"ref_39","unstructured":"(2023, November 18). Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis, Available online: https:\/\/www.clinicaltrials.gov\/search?cond=NCT05247866."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1007\/s12325-017-0525-8","article-title":"RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 \u03b11 and \u03b12 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study","volume":"34","author":"Tripp","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1053\/j.gastro.2018.10.051","article-title":"RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients with Eosinophilic Esophagitis","volume":"156","author":"Hirano","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.cgh.2020.03.036","article-title":"Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients with Eosinophilic Esophagitis","volume":"19","author":"Dellon","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jaci.2020.03.045","article-title":"An anti-IL-13 antibody reverses epithelial-mesenchymal transition biomarkers in eosinophilic esophagitis: Phase 2 trial results","volume":"146","author":"Gann","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_44","unstructured":"(2023, November 24). A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants with Eosinophilic Esophagitis, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT04753697?cond=NCT04753697&rank=1."},{"key":"ref_45","unstructured":"(2023, November 24). Safety Study of CC-93538 in Adult and Adolescent Participants with Eosinophilic Esophagitis, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT04991935?cond=NCT04991935&rank=1."},{"key":"ref_46","unstructured":"(2023, November 24). A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants with Active Eosinophilic Esophagitis Receiving Cendakimab, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT05175352?cond=NCT05175352&rank=1."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e13444","DOI":"10.7717\/peerj.13444","article-title":"IL-4\/IL-13 axis as therapeutic targets in allergic rhinitis and asthma","volume":"10","author":"Wong","year":"2022","journal-title":"PeerJ"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2014.07.049","article-title":"Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis","volume":"135","author":"Rothenberg","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1111\/all.13451","article-title":"Immunological and hematological effects of IL-5(R\u03b1)-targeted therapy: An overview","volume":"73","author":"Hassani","year":"2018","journal-title":"Allergy"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/ACI.0000000000000741","article-title":"Biologics in eosinophilic esophagitis","volume":"21","author":"Zhang","year":"2021","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.jaci.2020.01.051","article-title":"Esophageal type 2 cytokine expression heterogeneity in eosinophilic esophagitis in a multisite cohort","volume":"145","author":"Dunn","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jaci.2006.09.007","article-title":"Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis","volume":"118","author":"Stein","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: A randomised, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2011.07.044","article-title":"An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis","volume":"141","author":"Gupta","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1136\/gutjnl-2023-330337","article-title":"Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: A multicentre, randomised, double-blind, placebo-controlled clinical trial","volume":"72","author":"Dellon","year":"2023","journal-title":"Gut"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaci.2011.11.044","article-title":"Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial","volume":"129","author":"Spergel","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/MPG.0000000000001840","article-title":"Safety and Efficacy of Reslizumab for Children and Adolescents with Eosinophilic Esophagitis Treated for 9 Years","volume":"66","author":"Markowitz","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2147\/DDDT.S155307","article-title":"Benralizumab in the treatment of severe asthma: Design, development and potential place in therapy","volume":"12","author":"Pelaia","year":"2018","journal-title":"Drug Des. Devel Ther."},{"key":"ref_59","unstructured":"(2023, November 24). A Study of Benralizumab in Patients with Eosinophilic Esophagitis (MESSINA), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04543409."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6452","DOI":"10.4049\/jimmunol.169.11.6452","article-title":"Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge","volume":"169","author":"Liu","year":"2002","journal-title":"J. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41577-022-00735-y","article-title":"Role of thymic stromal lymphopoietin in allergy and beyond","volume":"23","author":"Leonard","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.alit.2020.01.001","article-title":"Anti-TSLP antibodies: Targeting a master regulator of type 2 immune responses","volume":"69","author":"Nakajima","year":"2020","journal-title":"Allergol. Int."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"eadg6360","DOI":"10.1126\/scisignal.adg6360","article-title":"TSLP shapes the pathogenic responses of memory CD4+ T cells in eosinophilic esophagitis","volume":"16","author":"Rochman","year":"2023","journal-title":"Sci. Signal"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40265-022-01679-2","article-title":"Tezepelumab: First Approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Youngblood, B.A., Leung, J., Falahati, R., Williams, J., Schanin, J., Brock, E.C., Singh, B., Chang, A.T., O\u2019Sullivan, J.A., and Schleimer, R.P. (2020). Discovery, Function, and Therapeutic Targeting of Siglec-8. Cells, 10.","DOI":"10.3390\/cells10010019"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000501637","article-title":"AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity against Human Eosinophils and Inhibits Mast Cell-Mediated Anaphylaxis in Mice","volume":"180","author":"Youngblood","year":"2019","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e126219","DOI":"10.1172\/jci.insight.126219","article-title":"Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis","volume":"4","author":"Youngblood","year":"2019","journal-title":"JCI Insight"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41385-020-00336-9","article-title":"A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation","volume":"14","author":"Schanin","year":"2021","journal-title":"Mucosal Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.14309\/01.ajg.0000858424.48968.ad","article-title":"Results from KRYPTOS, a Phase 2\/3 Study of Lirentelimab (AK002) in Adults and Adolescents with EoE","volume":"117","author":"Dellon","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1136\/gutjnl-2023-329873","article-title":"Comparison of drugs for active eosinophilic oesophagitis: Systematic review and network meta-analysis","volume":"72","author":"Visaggi","year":"2023","journal-title":"Gut"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.cytogfr.2013.05.004","article-title":"The role of IL-15 in gastrointestinal diseases: A bridge between innate and adaptive immune response","volume":"24","author":"Pagliari","year":"2013","journal-title":"Cytokine Growth Factor. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/19420862.2017.1332553","article-title":"Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis","volume":"9","author":"Vicari","year":"2017","journal-title":"mAbs"},{"key":"ref_74","unstructured":"(2023, November 25). A Multicentre, SAD, and MAD Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IV Treatment of CALY-002 in Healthy Subjects and Subjects with Celiac Disease and Eosinophilic Esophagitis, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04593251?cond=NCT04593251&draw=2&rank=1."},{"key":"ref_75","unstructured":"(2023, November 25). A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The \u201cEvolvE\u201d Study), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05774184?cond=barzolvolimab&draw=2&rank=1."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/all.15585","article-title":"Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria","volume":"78","author":"Hawro","year":"2023","journal-title":"Allergy"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Loizou, D., Enav, B., Komlodi-Pasztor, E., Hider, P., Kim-Chang, J., Noonan, L., Taber, T., Kaushal, S., Limgala, R., and Brown, M. (2015). A pilot study of omalizumab in eosinophilic esophagitis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0113483"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1053\/j.gastro.2014.05.036","article-title":"Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE","volume":"147","author":"Clayton","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaci.2008.06.012","article-title":"Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis","volume":"122","author":"Straumann","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_80","first-page":"457","article-title":"A New Tool to Assess Disease Severity in Eosinophilic Esophagitis","volume":"19","author":"Dellon","year":"2023","journal-title":"Gastroenterol. Hepatol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/3\/1702\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:51:48Z","timestamp":1760104308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/3\/1702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":80,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["ijms25031702"],"URL":"https:\/\/doi.org\/10.3390\/ijms25031702","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,30]]}}}